Differences in Pharmacokinetic/Pharmacodynamic Parameters of Tedizolid Against VRE and MRSA

Liu, Xiaoxi; Tashiro, Syoichi; Igarashi, Yuki; Takemura, Wataru; Kojima, Nana; Morita, Takumi; Hayashi, Masako; Enoki, Yuki; Taguchi, Kazuaki; Matsumoto, Kazuaki

doi:10.1007/s11095-022-03425-5

Cited by 9 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5.1.5. The Potential Role of TDM LC-MS/MS methods are available in the literature to monitor tedizolid concentrations in clinical practice [161][162][163]. However, no safety and/or efficacy clinical cutoff for tedizolid trough concentrations has yet been identified, and a TDM of tedizolid is presently considered unnecessary [164].…”

Section: Pk/pd Characteristicsmentioning

confidence: 99%

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

Carcione,

Intra,

Andriani

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Antibiotic resistance is a public health problem with increasingly alarming data being reported. Gram-positive bacteria are among the protagonists of severe nosocomial and community infections. The objective of this review is to conduct an extensive examination of emerging treatments for Gram-positive infections including ceftobiprole, ceftaroline, dalbavancin, oritavancin, omadacycline, tedizolid, and delafloxacin. From a methodological standpoint, a comprehensive analysis on clinical trials, molecular structure, mechanism of action, microbiological targeting, clinical use, pharmacokinetic/pharmacodynamic features, and potential for therapeutic drug monitoring will be addressed. Each antibiotic paragraph is divided into specialized microbiological, clinical, and pharmacological sections, including detailed and appropriate tables. A better understanding of the latest promising advances in the field of therapeutic options could lead to the development of a better approach in managing antimicrobial therapy for multidrug-resistant Gram-positive pathogens, which increasingly needs to be better stratified and targeted.

show abstract

Section: Pk/pd Characteristicsmentioning

confidence: 99%

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

Carcione,

Intra,

Andriani

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…32−34 Presently, MRSA and VRE are two major causes of nosocomial infections, while the available drugs for treating them are limited. 34 Thus, selective inhibition of G+ bacteria is of significance in practice. 35,36 Fortunately, compared with the cell wall structure of Gram-negative (G−) bacteria, the G+ bacterial cell walls do not contain an outer membrane composed of lipids, proteins, and lipopolysaccharides, making them more susceptible to antibiotics or other antibacterial agents.…”

Section: Introductionmentioning

confidence: 99%

“…In the past decades, the rapid evolution of drug-resistant bacteria has become a global challenge due to the abuse of antibiotics. − Particularly, Gram-positive (G+) drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), have captured much attention. − Presently, MRSA and VRE are two major causes of nosocomial infections, while the available drugs for treating them are limited . Thus, selective inhibition of G+ bacteria is of significance in practice. , Fortunately, compared with the cell wall structure of Gram-negative (G−) bacteria, the G+ bacterial cell walls do not contain an outer membrane composed of lipids, proteins, and lipopolysaccharides, making them more susceptible to antibiotics or other antibacterial agents. − Meanwhile, bacteria prefer to use d -amino acids in the biosynthesis of the peptidoglycan cell wall, while mammalian cells exclusively uptake l -amino acids. − This property reveals the feasibility of d -amino acids for the selective killing of G+ bacteria. − …”

Section: Introductionmentioning

confidence: 99%

Chiral Sulfur Nanosheets for Dual-Selective Inhibition of Gram-Positive Bacteria

Huang

Zhang

et al. 2023

ACS Nano

View full text Add to dashboard Cite

Elemental sulfur is the oldest known antimicrobial agent. However, conventional sulfur in the clinic suffers from poor aqueous solubility and limited antibacterial activity, greatly hindering its practical use. Herein, we report a reform strategy coupling dimension engineering with chirality transfer to convert conventional 3D sulfur particles into chiral 2D sulfur nanosheets (S-NSs), which exhibit 50-fold improvement of antibacterial capability and dualselective inhibition against Gram-positive bacteria. Benefiting from the inherent selectivity of S-NSs and chirality selectivity from decorated Dhistidine, the obtained chiral S-NSs are proven to precisely kill Gram-positive drug-resistant bacteria, while no obvious bacterial inhibition is observed for Gram-negative bacteria. Mechanism studies reveal that S-NSs produce numerous reactive oxygen specipoes and hydrogen sulfide after incubation with bacteria, thus causing bacterial membrane destruction, respiratory chain damage, and ATP production inhibition. Upon spraying chiral S-NSs dispersions onto MRSA-infected wounds, the skin healing process was greatly accelerated in 8 days due to metabolism inhibition and oxidative damage of bacteria, indicating the excellent treatment efficiency of MRSA-infected wounds. This work converts the traditional well-known sulfur into modern antibacterial agents with a superior Gram-selectivity bactericidal capability.

show abstract

Antimicrobial Efficacy Evaluations of Metronidazole against Clostridioides difficile Infection using Fecal Pharmacokinetic and Pharmacodynamic Analyses

et al. 2023

View full text Add to dashboard Cite

Differences in Pharmacokinetic/Pharmacodynamic Parameters of Tedizolid Against VRE and MRSA

Cited by 9 publications

References 27 publications

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

Chiral Sulfur Nanosheets for Dual-Selective Inhibition of Gram-Positive Bacteria

Antimicrobial Efficacy Evaluations of Metronidazole against Clostridioides difficile Infection using Fecal Pharmacokinetic and Pharmacodynamic Analyses

Contact Info

Product

Resources

About